TNFAIP3: A Potential Drug Target and Biomarker (G7128)

Target Name: TNFAIP3

NCBI ID: G7128

TNFAIP3

TNFAIP3: A Potential Drug Target and Biomarker

Tumor Necrosis Factor-Inflamed Protein (TNFAIP3) is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. The protein is a key player in the immune response and has been implicated in the development and progression of several diseases. In this article, we will explore the potential drug target and biomarker properties of TNFAIP3, as well as its current research and development status.

Potential Drug Target

TNFAIP3 is a protein that is expressed in various tissues and has been implicated in the immune response. It has been shown to play a role in the regulation of inflammation and immune cell function. Several studies have suggested that TNFAIP3 may be a potential drug target due to its unique structure and its involvement in the immune response.

One of the key reasons for the potential drug target status of TNFAIP3 is its unique structure. TNFAIP3 is a transmembrane protein that is composed of four intracellular domains: an extracellular domain, a transmembrane domain, an intracellular domain, and an N-terminal domain. The extracellular domain of TNFAIP3 contains a catalytic site that is involved in the regulation of protein-protein interactions and may be a potential drug target.

In addition to its unique structure, TNFAIP3 has also been shown to play a role in the regulation of the immune response. Several studies have shown that TNFAIP3 is involved in the regulation of T cell development and function. For example, one study published in the journal Nature Medicine showed that inhibiting the activity of TNFAIP3 using small interfering RNA (siRNA) led to a decrease in the production of IFN-纬, a cytokine that is involved in the regulation of the immune response.

Potential Biomarker

TNFAIP3 has also been suggested as a potential biomarker for several diseases, including cancer. The protein has been shown to be expressed in various tissues, including the tumor, and has been used as a biomarker for cancer diagnosis and treatment. In addition, TNFAIP3 has been shown to be involved in the regulation of cancer cell growth and has been shown to inhibit the growth of cancer cells in cell culture.

Current Research and Development Status

Several studies have explored the potential drug target and biomarker properties of TNFAIP3. One study published in the journal Cancer Research showed that the inhibition of TNFAIP3 using a small interfering RNA (siRNA) led to a decrease in the production of TNF-伪, a pro-inflammatory cytokine that has been shown to contribute to the development of cancer.

Another study published in the journal Molecular Therapy showed that TNFAIP3 was expressed in various tissues, including the tumor, and was shown to be involved in the regulation of cancer cell growth. The study also showed that inhibiting the activity of TNFAIP3 using a small interfering RNA (siRNA) led to a decrease in the growth of cancer cells in cell culture.

Conclusion

TNFAIP3 is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and its involvement in the immune response make it an attractive target for drug development. Further research is needed to fully understand the potential drug target and biomarker properties of TNFAIP3 and to develop safe and effective treatments for various diseases.

Protein Name: TNF Alpha Induced Protein 3

Functions: Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of pro-inflammatory cytokines and IFN beta in LPS-tolerized macrophages

The "TNFAIP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNFAIP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets